Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Technetium 99m evuzamitide - Attralus

Next Previous
Drug Profile

Technetium 99m evuzamitide - Attralus

Alternative Names: 99mTc-p5+14; AT-05

Latest Information Update: 21 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Attralus
  • Class Diagnostic conjugates; Heavy metals; Imaging agents; Peptide diagnostics; Radioisotopes; Radiopharmaceutical diagnostics; Technetium compounds
  • Mechanism of Action Emission-computed tomography enhancers; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Amyloidosis

Most Recent Events

  • 12 Jan 2026 Bayer acquires Technetium 99m evuzamitide (AT 05) from Attralus
  • 08 Oct 2025 Technetium 99m evuzamitide is still in phase I trial for Amyloidosis (Diagnosis) in USA (IV) (NCT05951816)
  • 01 Apr 2025 Updated pharmacokinetics data from a phase I trial in Amyloidosis released by Attralus

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top